N-(1-甲基-3-氧代丁基)-乙酰胺 | 212831-40-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: N-(1-甲基-3-氧代丁基)-乙酰胺
• 英文名称: N-(1-methyl-3-oxo-butyl)acetamide
• 英文别名: N-(4-oxopentan-2-yl)acetamide
• CAS: 212831-40-8
• 化学式: C₇H₁₃NO₂
• mdl: MFCD18823424
• 分子量: 143.186
• InChiKey: KZFUTYXONYHVAM-UHFFFAOYSA-N

物化性质

• 沸点：
  304.9±25.0 °C(Predicted)
• 密度：
  0.970±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  46.2
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 N-(1-甲基-3-氧代丁基)-乙酰胺 在 高氯酸 作用下， 反应 1.0h， 以81%的产率得到Acetic acid 2,4,6-trimethyl-5,6-dihydro-4H-[1,3]oxazin-6-yl ester; compound with perchloric acid
  参考文献：
  名称：

  N-3-oxoalkylamides and-thioamides in synthesis of heterocyclic compounds.

  摘要：

  DOI：

  10.1007/bf02291650
• 作为产物：
  描述：

  Diacetyl-mono-isopropylimin 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以188 mg的产率得到N-(1-甲基-3-氧代丁基)-乙酰胺
  参考文献：
  名称：

  I₂-Catalyzed C–O Bond Formation and Dehydrogenation: Facile Synthesis of Oxazolines and Oxazoles Controlled by Bases

  摘要：

  A general method for the synthesis of oxazolines and oxazoles was developed through I-2-catalyzed C-O bond formation and dehydrogenation with the same oxidant, TBHP. By simply tuning reaction bases, either oxazolines or oxazoles were selectively produced from beta-acylamino ketones.

  DOI：

  10.1021/acs.orglett.5b01933

文献信息

• Evidence That Protons Can Be the Active Catalysts in Lewis Acid Mediated Hetero-Michael Addition Reactions
  作者：Tobias C. Wabnitz、Jin-Quan Yu、Jonathan B. Spencer

  DOI：10.1002/chem.200305407

  日期：2004.1.23

  mechanism of Lewis acid catalysed hetero-Michael addition reactions of weakly basic nucleophiles to alpha,beta-unsaturated ketones was investigated. Protons, rather than metal ions, were identified as the active catalysts. Other mechanisms have been ruled out by analyses of side products and of stoichiometric enone-catalyst mixtures and by the use of radical inhibitors. No evidence for the involvement

  研究了路易斯酸催化弱碱性亲核试剂对α，β-不饱和酮的杂-迈克尔加成反应的机理。质子而不是金属离子被鉴定为活性催化剂。通过分析副产物和化学计量的烯酮-催化剂混合物以及通过使用自由基抑制剂，已经排除了其他机理。没有获得有关π-烯烃-金属配合物或羰基-金属-离子相互作用的证据。在非配位碱2，6-二叔丁基吡啶的存在下，反应没有进行。获得了良好的催化活性与阳离子水解常数的相关性。一羰基和二羰基底物的不同反应性已得到合理化。建立了一种用于评估质子生成的（1）H NMR探针，并且根据路易斯酸在有机溶剂中的水解倾向对其进行了分类。研究了氮，氧，硫和碳亲核试剂的布朗斯台德酸催化共轭加成反应，并讨论了不对称路易斯酸催化的意义。
• [EN] SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME<br/>[FR] TRIAZOLES AMINO-SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：INST DRUG DELIVERY

  公开号：WO2015095701A1

  公开（公告）日：2015-06-25

  Disclosed are novel substituted amino triazoles of Formula (I), and pharmaceutically acceptable salts thereof. The compounds of Formula (I) are inhibitors of Acidic mammalian chitinase (AMCase) and are useful, in a non-limiting example, for treating asthma. Also provided are pharmaceutical compositions containing at least one compound of the present invention, or a pharmaceutically acceptable salt, hydrate or solvate thereof, and at least one pharmaceutically acceptable carrier, solvent, adjuvant or diluent, and methods of using such compounds and/or compositions to treat asthma and/or to monitor asthma treatment.

  公开了化合物的新型替代氨基三唑的结构，其化学式为（I），以及其药学上可接受的盐。化合物的化学式（I）是酸性哺乳动物几丁质酶（AMCase）的抑制剂，并且在非限制性示例中用于治疗哮喘。还提供了含有本发明至少一种化合物或其药学上可接受的盐、水合物或溶剂化合物的药物组合物，以及至少一种药学上可接受的载体、溶剂、辅料或稀释剂，并使用这些化合物和/或组合物来治疗哮喘和/或监测哮喘治疗的方法。
• SUBSTITUTED AMINO TRIAZOLES, AND METHODS USING SAME
  申请人：Institute for Drug Discovery, LLC

  公开号：EP3082805B1

  公开（公告）日：2020-02-05
• [EN] USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS<br/>[FR] UTILISATION DE PROMÉDICAMENTS POUR ÉVITER LES ÉVÉNEMENTS INDÉSIRABLES À MÉDIATION GI
  申请人：SHIRE LLC

  公开号：WO2012046062A1

  公开（公告）日：2012-04-12

  The present invention relates to prodrugs of a wide variety of drugs and pharmaceutical compositions containing such prodrugs. Methods for minimizing locally mediated (from within the gut lumen) adverse gastrointestinal events associated with the underivatised drug and increasing the sustainment of plasma drug levels with the aforementioned prodrugs are also provided. Thus, the present invention relates to the use of prodrugs of a wide diversity of drugs (other than opioids) to transiently inactivate them and so reduce directly, locally mediated adverse gastrointestinal (GI) side–effects normally evident after administration of the parent compound. Additionally, such prodrugs may confer improved pharmacokinetics.
• I₂-Catalyzed C–O Bond Formation and Dehydrogenation: Facile Synthesis of Oxazolines and Oxazoles Controlled by Bases
  作者：Wen-Chao Gao、Fei Hu、Yu-Ming Huo、Hong-Hong Chang、Xing Li、Wen-Long Wei

  DOI：10.1021/acs.orglett.5b01933

  日期：2015.8.7

  A general method for the synthesis of oxazolines and oxazoles was developed through I-2-catalyzed C-O bond formation and dehydrogenation with the same oxidant, TBHP. By simply tuning reaction bases, either oxazolines or oxazoles were selectively produced from beta-acylamino ketones.